Center for Blood Cancers | NYU Langone Health
Experts at the Center for Blood Cancers, part of Perlmutter Cancer Center, treat blood cancers such as leukemia, lymphoma, and multiple myeloma.
sustainability-report.pdf
... . Our longstanding and robust energy management program focuses on resilient infrastructure design ... focus on creating consistent, institution-wide policies and programs that drive optimal and sustainable ...
A SINGLE CENTER PILOT STUDY ESTABLISHING TEST-RETEST RELIABILITY OF SWALLOWING PRESSURES COLLECTED WITH HIGH RESOLUTION PHARYNGEAL MANOMETRY (HRPM)
Difficulty swallowing (known as dysphagia) can have devastating consequences for health and quality of life. The current gold-standard assessment tool, videofluoroscopy (VF), allows real time visualization of swallowing via a video x-ray. Unfortunately, VF exposes the patient to radiation and therefore is limited in its use. A relatively new technique for quantifying swallowing physiology is called High Resolution Pharyngeal Manometry (HRPM) - it registers the pressures generated by the swallowing muscles on a catheter passed through the nose to the esophagus. Our team (speech pathology, otolaryngology, gastroenterology) recently acquired an HRPM system and is eager to employ it in our research grants with a focus on aging, disease progression, and treatment for swallowing disorders. However, at this time, very little is known about the test-retest reliability of this tool which leaves us unable to conduct realistic power calculations in these proposals. Therefore, we will plan to collect VF/HRPM test-retest data in 20 older adults two weeks apart.
complete-chna-csp-appendices-june-2016.pdf
... Programs, NYU Lutheran at: kathleen.hopkins@nyumc.org. 1 Table of Contents Section Pages Overview 1 ... and City public health priorities 17 Addressing health disparities 17 1 Section Pages Our Programs 20 ...
Diagnosing Epilepsy & Seizure Disorders in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone use exams, tests, and EEG to diagnose epilepsy and seizure disorders.
Pediatric Congenital Heart Program | NYU Langone Health
The Pediatric Congenital Heart Program at Hassenfeld Children’s Hospital offers innovative care for people with congenital heart conditions.
Gastrointestinal tract colonization and Staphylococcus aureus associated skin diseases
Our ultimate goal is to improve our understanding of the complex interplay of host, pathogen, and microbiome in Staphylococcus aureus-associated skin diseases. These diseases include both frank infection such as skin and soft tissue infections (SSTIs) and inflammatory diseases with a known high burden of Staphylococcus aureus colonization such as atopic dermatitis. We believe a deeper understanding of the perturbations of S. aureus colonization versus infection and contributions of human host genetics to these perturbations will provide strategies for improved prevention and treatment recommendations.S. aureus gastrointestinal (GI) colonization is an understudied aspect of cutaneous disease and may represent a reservoir for colonization and recurrent infection. The focus of the present proposal will be to determine the role of GI colonization in two syndromes: S. aureus skin abscesses (SSTI; an infection) and atopic dermatitis (AD; a S. aureus-associated skin disease). Furthermore, given that understanding commensal interactions requires consideration of not only environmental but host factors, we will test for an association between GI colonization, microbiota, and host susceptibility gene ATG16L1. ATG16L1 is implicated in inflammatory bowel disease, and our recent work demonstrates that it is associated with S. aureus GI tract colonization in mice. Toward these ends, we will obtain patient data and biobank stool, peripheral blood, and S. aureus from both sets of patients.
Investigation of cellular and molecular interactions in inflammation angiogenesis and immunity in human atherosclerosis: the ATHERO-IN study
Atherosclerotic cardiovascular disease (ACVD) is driven by inflammation and is the leading cause of mortality and disability worldwide, even in optimally treated patients. The impact of many immune cells (inflammatory cells) on atherosclerosis progression is well-established, the contribution of different immune and non-immune cells to human disease pathology and cardiovascular (CV) events remain largely unknown. It is well established that specific histological features of plaque instability are associated with increased risk for cardiovascular events (i.e. stroke, heart attack). This study will address the following knowledge gaps. The ATHERO-IN study is a prospective and retrospective, multisite, observational study. The study will be conducted at two study sites: 1. the NYU Langone Health (coordinating and recruitment site) and 2. the Icahn School of Medicine at Mount Sinai (recruitment site). The Focus of the study is atherosclerotic cardiovascular disease and inflammation. The Goal of the study is to identify new cellular and molecular determinant of atherosclerosis, plaque pathology and cardiovascular events. To achieve this goal, we will use a system biology approach to analyze human samples that will be obtained from patients with atherosclerotic cardiovascular disease from the NYU Langone Health System (NYULH) and from the Mount Sinai Health System (MSHS).
Obstetrics & Gynecology | NYU Langone Health
At NYU Langone, our obstetrician–gynecologists provide experienced and compassionate care to people of all ages and gender identities.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol: ATRI-001
Discover, optimize, standardize, and validate clinical trial measures and biomarkers used in ongoing AD research.Aim 1. Longitudinal changes in cognition and associated biomarkersDetermine and define those measures of cognition and function, including composite measures, and those biomarker measures, which capture longitudinal change with the highest statistical power to detect treatment effects in clinical trials.Longitudinal change of cerebral tau measured with 18F-AV-1451 PET (AV-1451) will be correlated/compared with other measures.Aim 2. Prediction of cognitive declineDetermine which clinical, cognitive, and biomarker measures that best predict decline of cognition in CN, MCI, and AD participants. In addition, determine which biomarker changes correlate with cognitive decline, with focus on AV-1451 PET.Aim 3. ValidationValidate biomarker measures obtained at Baseline and longitudinally by correlating results with “gold standard” clinical measurements and pathology.Aim 4. Clinical trial designDetermine the optimum outcome measures with attention to cognitive decline and AV-1451 PET, predictors of cognitive decline, and inclusion/exclusion criteria for clinical trials of cognitively normal participants (for secondary preclinical AD trials), MCI patients (for prodromal AD trials) and participants with early dementia due to AD.Aim 5. DiscoveryTo determine the effects of other known disease proteins found in AD brains and genes, as well as newly discovered genes, proteins, and analytes that provide useful information concerning the pathogenesis/diagnosis of AD.Protocol Clarifications:only those with the capacity to consent will be considered for retention in the ADNI study.